Rutgers Cancer Institute

Vanessa Broadhurst

jfa77 — Tue, 01 Jul 2025 16:07:12 +0000

Vanessa Broadhurst

Vanessa Broadhurst is the Executive Vice President of Global Corporate Affairs and an executive committee member at Johnson & Johnson. Vanessa is responsible for advancing strategies across Corporate Marketing, Global Communications, Global Health Equity, and Worldwide Government Affairs & Policy. She leads and mentors a world-class team who are passionate about transforming health for humanity.

Vanessa has more than 25 years of senior leadership experience, having worked for leading global healthcare companies in the U.S. and Europe including Amgen, Novartis, and Abbott.

Prior to her current position, Vanessa served as Company Group Chairman of Global Commercial Strategy for Johnson & Johnson’s Innovative Medicine sector, where she led efforts focused on commercialization and launch strategies that spanned a broad pipeline of products and realized accelerated business growth across six therapeutic areas. During her tenure, Vanessa was a member of the Pharmaceuticals Group Operating Committee, the Research and Development Senior Leadership Team, and responsible for Global Value and Access, Global Commercial Data Sciences, and Global Medical Affairs.

At Johnson & Johnson Vanessa has led several of its U.S. businesses including Cardiovascular and Metabolism, Internal Medicine, and Infectious Disease, where she consistently delivered significant bottom-line growth and helped grow Johnson & Johnson to become one of the largest and most diversified healthcare companies in the world.

Vanessa sits on the Board of Directors of Zoetis and is a member of The Executive Leadership Council (ELC).

Vanessa holds a Master of Business Administration from the Ross School of Business at the University of Michigan and a Bachelor of Arts degree from the University of Colorado, Boulder.

jfa77 Tue, 07/01/2025 - 12:07

Gynecologic Cancers Fact Sheet

jfa77 — Mon, 30 Jun 2025 19:19:53 +0000

Gynecologic Cancers Fact Sheet jfa77 Mon, 06/30/2025 - 15:19

File

Gynecologic-Cancers-Fact-Sheet.pdf

Kimberly L. Pham, MD

jfa77 — Wed, 25 Jun 2025 12:32:48 +0000

Physician Profile

jfa77 Wed, 06/25/2025 - 08:32

Kimberly L. Pham, MD

Outpatient Palliative Care Physician

Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School

I am an Assistant Professor in the Department of Medicine, Division of Medical Oncology, Palliative Care section at Rutgers Robert Wood Johnson Medical School. I received my medical degree from Saint George’s University. I completed internal medicine residency at Creighton University – Phoenix and followed with a Hospice and Palliative Medicine fellowship at University of Arizona – Phoenix.

My clinical work as an outpatient palliative medicine physician focuses on symptom management and clarifying goals of care in patients with serious illness. In addition to clinical and research work, I work with undergraduates, medical/NP/PA students, residents, and fellows. I am core faculty for the Rutgers hospice and palliative medicine physician fellowship program.

I live in NJ with my family and cat and enjoy running, hiking, and long evenings watching videos about cooking, hobbies, and home design.

Clinical Expertise

Symptom management & goals of care

Palliative Medicine and Supportive Care Program

false

RWJBarnabas Health, Rutgers Cancer Institute Welcome First Patients to New Jersey’s Only Freestanding Cancer Hospital

jfa77 — Tue, 24 Jun 2025 16:46:12 +0000

RWJBarnabas Health, Rutgers Cancer Institute Welcome First Patients to New Jersey’s Only Freestanding Cancer Hospital

Jack & Sheryl Morris Cancer Center Is Now Officially Open

jfa77 Tue, 06/24/2025 - 12:46

5 year old patient Serina Patel and her family join the leadership of RWJBarnabas Health, Rutgers Cancer Institute and Robert Wood Johnson University Hospital and the Rutgers Scarlet Knight at the opening of the new Jack & Sheryl Morris Cancer Center

NEW BRUNSWICK, N.J., June 24, 2025 – RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center officially opened the doors of the 12-story, 520,000 square-foot, state-of-the-art Jack & Sheryl Morris Cancer Center — the state’s only freestanding, comprehensive cancer hospital, one of just 13 in the nation.

Patients arriving for their first appointments were greeted with warm welcomes by hospital leaders and staff, dedicated to providing world-class cancer care. Yesterday’s opening was marked by an atmosphere of hope and inspiration. Visitors were also greeted by beloved, iconic New Jersey mascots — NJ Devil, Rutgers Scarlet Knight, and Sparkee from the Somerset Patriots.

New Jersey Devils N.J., and Somerset Patriots Sparkee visit with patients and employees to celebrate the opening of the Jack & Sheryl Morris Cancer Center

“Today is a terrific day,” said Mark E. Manigan, President and Chief Executive Officer for RWJBarnabas Health. “This building is emblematic of our $1.5 billion investment in transforming the prevention, diagnosis and treatment of cancer in New Jersey and beyond. It’s the only one of its kind in the region—one of just 13 in the country—with scientists on one side and clinicians on the other, literally bringing advancements in cancer care from the bench to the patient. Irrespective of where you live, you’ll have access to what’s happening here, and by virtue of that, we will elevate the quality of cancer care and experience for every patient we serve.”

The Jack & Sheryl Morris Cancer Center is the cornerstone of RWJBarnabas Health’s more than $1.5 billion investment to expand oncology services across the state. Equipped with the most advanced technology and designed to facilitate multidisciplinary, patient-centered care, the Center redefines what it means to provide hope and healing.

Leadership from RWJBarnabas Health, Rutgers Cancer Institute and Robert Wood Johnson University Hospital thank the employees of the new Jack & Sheryl Morris Cancer Center – now opened for patients

Dr. Steven Libutti, William N. Hait Director of Rutgers Cancer Institute and Senior VP of Oncology Services, RWJBarnabas Health, with the Rutgers Scarlet Knight to commemorate the start of patient care at the Jack & Sheryl Morris Cancer Center

“This hospital is the culmination of years of collaboration, vision, and dedication to advancing cancer research and treatment,” said Steven Libutti, MD, William N. Hait Director of Rutgers Cancer Institute and Senior Vice President of Oncology Services at RWJBarnabas Health. “We are creating a new standard of care where scientific discovery and compassionate treatment intersect under one roof. We’re not just treating cancer, we’re transforming lives.”

Hospital namesake Jack Morris, Chair of the Board of Directors at Robert Wood Johnson University Hospital, also shared his thoughts on the opening: “We saw upwards of 500 patients on our first day. This cancer center will raise the bar for cancer care throughout the United States. This is an amazing opportunity for the people who care for patients and the patients we care for. We can already see what this will do for the state of New Jersey, and that makes my family and I very happy.”

The Jack & Sheryl Morris Cancer Center features: 88 infusion bays and 80 exam rooms for adult and pediatric outpatient care, the infrastructure to enhance the development and deployment of the latest innovative clinical trials; a vibrant, “Jersey Shore”-themed clinical space for pediatric patients; advanced radiation oncology and diagnostics; on-site pharmacy; and state-of-the-art laboratories to support 10 independent research teams. It also includes 96 inpatient beds and a dedicated floor for surgical and procedure rooms. As part of a planned phased-in opening, inpatient care is expected to begin in late summer.

CLICK HERE to access a multimedia toolkit to view/download videos and photos.

###

ABOUT RWJBARNABAS HEALTH

RWJBarnabas Health is New Jersey’s largest and most comprehensive academic health system, caring for more than five million people annually. Nationally renowned for quality and safety, the system includes 14 hospitals and 9,000 affiliated physicians integrated to provide care at more than 700 patient care locations.

RWJBarnabas Health partners with its diverse communities to build and sustain a healthier New Jersey. It provides patient-centered care in a compassionate and equitable manner and is the state’s largest safety-net provider and leader in addressing the social determinants of health. RWJBarnabas Health provides food to the hungry, housing for the homeless and economic opportunities to those most vulnerable.

RWJBarnabas Health’s commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute — the state's only NCI-designated Comprehensive Cancer Center, and Rutgers Robert Wood Johnson Medical School.

RWJBarnabas Health is among New Jersey’s largest private employers, with more than 43,000 employees, contributing more than $5.5 billion to the state economy every year. For more information, visit www.RWJBH.org.

ABOUT RUTGERS CANCER INSTITUTE

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, provides patients access to the most advanced cancer treatment options including clinical trials close to home at our facilities throughout the state. Our groundbreaking cancer research is the engine that drives access to the most advanced cancer treatments, where our discoveries become your care.

For journalists – contact:

Carrie Cristello
Carrie.Cristello@rwjbh.org

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

jfa77 — Thu, 19 Jun 2025 16:09:54 +0000

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma

jfa77 Thu, 06/19/2025 - 12:09

New Brunswick, N.J. and Boston, M.A., June 19, 2025 – Researchers from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, as well as Tufts Medical Center and The University of Manchester have developed and validated the first individualized risk prediction model for adults diagnosed with early-stage classic Hodgkin’s lymphoma. Known as the Early-stage Hodgkin International Prognostication Index (E-HIPI), the model estimates two-year progression-free survival (PFS) and is designed to support more personalized treatment planning for clinicians and patients.

The findings were published in the New England Journal of Medicine (NEJM) Evidence and presented concurrently by co-first and corresponding author, Andrew M. Evens, DO, MBA, MSc, Deputy Director for Clinical Services for the Rutgers Cancer Institute and Chief Physician Officer of the Jack & Sheryl Morris Cancer Center, during the 18th International Conference on Malignant Lymphoma (ICML), a leading global forum for lymphoma research and clinical advancements.

The E-HIPI model was developed using data from over 3,000 adult patients enrolled in four, pivotal international phase III clinical trials. To ensure its accuracy, it was tested and validated in two real-world registry cohorts that included more than 2,300 people with early-stage classic Hodgkin’s lymphoma. The model uses routinely available and objective clinical measures—like patient sex, tumor size, and exact values of common lab results such as hemoglobin and albumin levels—to help predict an individual patient’s chance of staying cancer-free for two years.

“Early-stage classic Hodgkin’s lymphoma is a highly curable cancer, particularly among young adults. However, despite high survival rates and significant advances in treatment, we’ve lacked a validated tool to assess outcomes and estimate a patient’s individual risk of relapse,” said Dr. Evens, who is also System Director of Medical Oncology and Oncology Lead, RWJBarnabas Health Medical Group, Associate Vice Chancellor for Clinical Innovation and Data Analytics at Rutgers Biomedical and Health Sciences. “Through this global collaboration with researchers at Tufts Medical Center, the University of Manchester in the United Kingdom, and all our international partners, we developed a robust, dynamic, and data-driven model that leverages common clinical variables to generate more precise predictive insights. This tool has the potential to enhance clinical decision-making, personalize treatment strategies, and ultimately improve long-term outcomes for patients worldwide.”

The E-HIPI model demonstrated strong and consistent performance across all datasets and outperformed the widely used European Organization for Research and Treatment of Cancer (EORTC) favorable/unfavorable classification. To facilitate real-world implementation, the research team developed interactive online risk calculators, to support shared decision-making between clinicians and patients. In addition to informing personalized treatment, the E-HIPI provides modernized risk stratification for the design of future clinical trials and research studies.

“We hope that this model will enhance communication between patients and clinicians, and promote a greater understanding of the short- and long-term risks and benefits of different treatment options for early-stage classic Hodgkin’s lymphoma,” said Susan K. Parsons, MD, MRP, medical director of the adolescent and young adult (AYA) cancer survivorship program, research director of the Center for Health Solutions at Tufts Medical Center, co-founder of the HoLISTIC Consortium, and co-senior author of the study. “Ideally, this type of information about treatment trade-offs will alleviate some of the burden experienced in the cancer journey."

“We rigorously developed and validated our model based on an established checklist for predictive modeling,” said Angie Mae Rodday, PhD, investigator in the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, biostatistician at the Tufts Clinical and Translational Science Institute and lead statistician for National Cancer Institute's funded project. “When we compared our model to existing classification systems, it had better performance and was more strongly related to patient outcomes. The online calculator we developed as a result of this work is accurate, accessible, easy-to-use and is completely free for patients and clinicians.”

This research was made possible through the HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) Consortium, a global effort combining data from seminal randomized clinical trials and cancer registries, which are enriched with long-term patient follow-up. The Consortium’s shared resources enabled the development and validation of the E-HIPI model and will continue to support its refinement as new data emerge, helping ensure its continued relevance in clinical practice. The E-HIPI builds on the success of the previously established A-HIPI (Advanced-stage Hodgkin lymphoma International Prognostication Index), which was also developed by investigators at RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and other centers and colleagues around the world. A-HIPI is a modern clinical decision tool designed to predict five-year progression-free and overall survival in adults with advanced-stage classic Hodgkin’s lymphoma. Together, these complementary models represent a significant step forward in advancing precision medicine across the full spectrum of Hodgkin’s lymphoma care. Investigators are actively pursuing next steps to further enhance individualized predictions by integrating different treatment regimens into the models as well as to estimate the risk of post-acute and late consequences that may occur years after therapy is completed.

Rachel Murphy-Banks, program manager of the Reid R. Sacco Adolescent & Young Adult Cancer Program at Tufts Medical Center and project manager of the HoLISTIC Consortium, was a key contributor to the visualization of the graphic interface.

“This research is a powerful example of what can be accomplished through international scientific collaboration,” said John Radford, MD, FMedSci, Professor of Medical Oncology at The University of Manchester, Consultant Medical Oncologist at The Christie NHS Foundation Trust, and co-lead of the Living With and Beyond Cancer Theme at the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, UK, who is co-senior author of the study. “Through the HoLISTIC Consortium, we brought together patient-level data from pivotal clinical trials and global cancer registries to develop a predictive model that is both rigorous and widely applicable. The success of this effort underscores the power of cross-border partnership, and its potential to deliver meaningful, real-world benefits to patients with Hodgkin’s lymphoma worldwide.”

About RWJBarnabas Health

RWJBarnabas Health partners with its diverse communities to build and sustain a healthier New Jersey. It provides patient-centered care in a compassionate and equitable manner and is the state’s largest safety-net provider and leader in addressing the social determinants of health. RWJBarnabas Health provides food to the hungry, housing for the homeless and economic opportunities to those most vulnerable.

RWJBarnabas Health’s commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute — the state's only NCI-designated Comprehensive Cancer Center, and Rutgers Robert Wood Johnson Medical School.

RWJBarnabas Health is among New Jersey’s largest private employers, with more than 43,000 employees, contributing more than $5.5 billion to the state economy every year. For more information, visit www.RWJBH.org.

About Rutgers Cancer Institute

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute in New Brunswick, Rutgers Cancer Institute at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

About Tufts Medicine

Tufts Medicine is an innovative health system that brings together the best of academic and community medicine to deliver exceptional, connected, and accessible care. Tufts Medicine is comprised of Tufts Medical Center, the principal teaching hospital of Tufts University and Tufts University School of Medicine, Lowell General Hospital, MelroseWakefield Hospital, Lawrence Memorial Hospital of Medford, Care at Home, and an integrated network of 2,300 physicians in Massachusetts and southern New Hampshire. We treat the most complex conditions, keep our communities healthy and bring research breakthroughs to life. Learn more at www.tuftsmedicine.org.

The University of Manchester

The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 52nd in the world (Academic Ranking of World Universities).

A truly international university, its community includes more than 44,000 students, 12,000 staff, and 550,000 alumni from 190 countries. Together, they are tackling the world’s biggest challenges – the University’s social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings).

The University is a powerhouse of research and discovery; 26 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government’s Research Excellence Framework (REF) 2021.

The institution is the most popular in the UK for undergraduate applications (UCAS 2023 cycle), and it is the most targeted university by the UK’s leading employers (The Graduate Market, 2024).

Learn more at www.manchester.ac.uk

About the National Institute for Health and Care Research (NIHR)

The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:

Funding high quality, timely research that benefits the NHS, public health and social care;
Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government.

For journalists – contact:

Krista Didzbalis
Corporate Communications Specialist, Strategic Communications, RWJBarnabas Health
732.507.8307
krista.didzbalis2@rwjbh.org

For patient appointments/inquiries – contact:

844-CANCERNJ (844-226-2376)

Jeremy Lechan
Media Relations Manager
Department of Marketing & Communications
508-333-4852
jlechan@tuftsmedicalcenter.org

Mike Addelman
Media Relations Officer
Animal Research Communications Lead
Faculty of Biology, Medicine and Health
University of Manchester
07717 881567
michael.addelman@manchester.ac.uk

Researcher Community Guide 2page

jfa77 — Tue, 17 Jun 2025 14:22:42 +0000

Researcher Community Guide 2page jfa77 Tue, 06/17/2025 - 10:22

File

Researcher-Community-Guide-2pg_0.pdf

Researcher Community Guide

jfa77 — Tue, 17 Jun 2025 14:21:49 +0000

Researcher Community Guide jfa77 Tue, 06/17/2025 - 10:21

File

Researcher-Community-Guide_0.pdf

Community Fundraising Guidelines

jfa77 — Fri, 13 Jun 2025 18:00:16 +0000

Community Fundraising Guidelines jfa77 Fri, 06/13/2025 - 14:00

File

Community-Fundraising-Guidelines.pdf

Community Fundraising Program

jfa77 — Fri, 13 Jun 2025 17:48:07 +0000

Community Fundraising Program

Thank you for your interest in fundraising on behalf of Rutgers Cancer Institute!

Download our Resource Guide & Toolkit →

Organizing a fundraiser is an excellent way to be a part of the Rutgers Cancer Institute community while helping to advance the very best in cancer research, treatment, and prevention. Funds raised allow Rutgers Cancer Institute to advance its mission in the fight against cancer.

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, provides patients access to the most advanced treatment options including clinical trials close to home at our facilities throughout the state. Our groundbreaking cancer research is the engine that drives access to the most advanced cancer treatments, where our discoveries become your care.

We rely on philanthropic support to pursue promising discoveries and ensure our physicians, researchers, and care teams are equipped to deliver exceptional patient care backed by the latest science. Contributions fuel research that leads to more effective diagnoses, treatment options, prevention methods, and detection of cancer.

Thank you for your dedication and commitment as you work toward making a difference through your organized event or initiative.

Stephanie Kenyon, Director of Development, Community Fundraising
848-932-7981
cancerphilanthropy@rutgersfoundation.org

jfa77 Fri, 06/13/2025 - 13:48

All external fundraising events or campaigns that are hosted by a third-party group or individual to benefit Rutgers Cancer Institute must be approved by our Office of Philanthropy prior to the beginning of any activities or promotional efforts.

Rutgers Cancer Institute is dedicated to helping individuals fight cancer. We take pride in safeguarding the integrity of our institution, its faculty and staff, and, most importantly, the patients we serve. Accordingly, these guidelines have been developed for individuals and organizations interested in raising funds on behalf of Rutgers Cancer Institute. This information will provide you with the necessary tools to get started and a clear understanding of our ability to support your fundraiser.

Download Our Resource Guide & Toolkit!

Learn how to get started, about our partner guidelines, financial guidelines and benefits of fundraising for Rutgers Cancer Institute. Download our resource guide & toolkit today.

Ready to Get Started?

After reviewing our resource guide and toolkit, please submit your interest on our designated form or contact us.

Patient Visit Guide

jfa77 — Wed, 11 Jun 2025 12:06:29 +0000

Patient Visit Guide jfa77 Wed, 06/11/2025 - 08:06

File

PFAC Visit Guide.pdf